BOC-D-LYS(Z)-OH

BOC-D-LYS(Z)-OH Property

Boiling point:

587.0±50.0 °C(Predicted)

Density 

1.176±0.06 g/cm3(Predicted)

storage temp. 

Sealed in dry,2-8°C

solubility 

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

form 

Powder

pka

3.99±0.21(Predicted)

Appearance

White to off-white Solid

optical activity

Consistent with structure

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H302Harmful if swallowed

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

BOC-D-LYS(Z)-OH Chemical Properties,Usage,Production

Chemical Properties

White powder

Synthesis

General procedure for the synthesis of (R)-6-(((benzyloxy)carbonyl)amino)-2-((tert-butoxycarbonyl)amino)hexanoic acid from N-(tert-butoxycarbonyl)-D-lysine and benzyl chloroformate: to an aqueous solution of 1 M NaOH (37 mL), N-(tert-butoxycarbonyl)-D-lysine (3.00 g, 12.2 mmol) was added at room temperature, then slowly dioxane was added until the suspension was completely dissolved. Subsequently, benzyl chloroformate (2.70 g, 15.9 mmol) was added dropwise over 30 min at 0 °C. The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the dioxane was removed by distillation under reduced pressure. The reaction mixture was acidified to pH 2 with 1 M HCl at 0 °C. The aqueous layer was extracted with EtOAc and the combined organic layers were dried with anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford the target compound 29 (4.4 g, 11.6 mmol, 95% yield) as a white foamy solid, which did not require further purification. 1H-NMR (360 MHz, CDCl3): δ (ppm) 7.37-7.23 (m, 5H), 6.18 (br s, 1H), 5.17-4.86 (m, 3H), 4.83 (s, 1H), 4.22-4.04 (m, 1H), 3.13-3.11 (m, 2H), 1.76-1.37 (m, 15H ). 13C-NMR (150 MHz, CDCl3): δ (ppm) 176.4 (CO), 156.8 (CO), 156.0 (CO), 136.6 (Cq), 128.7 (2 × CH), 128.3 (2 × CH), 128.1 (CH), 80.4 (Cq), 66.9 (CH2), 53.3 (CH). 40.7 (CH2), 32.0 (CH2), 29.3 (CH2), 29.5 (3×CH3), 22.1 (CH2). MS (ESI) m/z (%): (C14H20N2O4) 222 (14), (C7H12NO4) 174 (12), 128 (32), 108 (27), 92 (11), (C7H7) 91 (100), 84 (20), 57 (52), 41 (20). MS (ESI) m/z calculated value C14H20N2O4 [M+H-C5H9O2]+, 280.14; measured value, 280.14. LC-MS (ESI) m/z calculated value C19H28N2O6Na [M+Na]+, 403.2; measured value, 403.7. HPLC purity, 96%, tR = 19.7min, Gradient A.

References

[1] Journal of Medicinal Chemistry, 2016, vol. 59, # 5, p. 2222 - 2243
[2] Patent: WO2017/63910, 2017, A1. Location in patent: Page/Page column 38-39